Apellis Pharmaceuticals (NASDAQ:APLS) Posts Quarterly Earnings Results, Hits Estimates

Apellis Pharmaceuticals (NASDAQ:APLS) issued its quarterly earnings results on Tuesday. The company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54), Briefing.com reports. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. During the same period in the previous year, the firm posted ($1.56) EPS. The business’s revenue for the quarter was up 284.3% compared to the same quarter last year.

Apellis Pharmaceuticals Stock Performance

Shares of APLS traded down $1.73 on Wednesday, reaching $42.17. The company’s stock had a trading volume of 1,081,770 shares, compared to its average volume of 1,566,551. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. The stock has a market capitalization of $5.11 billion, a P/E ratio of -9.43 and a beta of 0.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The stock’s 50 day simple moving average is $54.74 and its two-hundred day simple moving average is $57.53.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on APLS shares. Raymond James increased their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday. Wedbush reduced their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $68.00 to $80.00 in a research note on Monday, February 5th. Finally, Oppenheimer upped their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $77.13.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 781 shares of Apellis Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the transaction, the general counsel now owns 103,390 shares in the company, valued at approximately $7,006,740.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 1,431 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $96,978.87. Following the transaction, the chief financial officer now owns 93,338 shares of the company’s stock, valued at $6,325,516.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 781 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at $7,006,740.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 376,427 shares of company stock valued at $23,169,639. Insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).